DSSO’s Head and Neck team is involved in a number of research programs that study various clinical and translation aspects of head and cancer prognostication and therapeutics. Clinical research is achieved through the establishment and enrichment of good clinical databases to answer specific clinical questions and dilemmas in head and neck oncology. Currently, an online database has been created to track outcomes of all head and neck oncology patients capturing the various treatment modalities that they receive sub-stratified by tumour subtype, stage and grade using the capabilities afforded by the REDCAP (Research Electronic Data Capture) relational database system. This system serves as the electronic platform via which cases are presented during the head and neck multidisciplinary tumour boards. Joint decisions are entered and recorded real-time at the meetings into the database for future research projects and audit purposes.
The team is also carrying out an in-depth Quality of Life (QOL) project aims to identify patients who require more intensive rehabilitation than what is currently offered. The team of doctors, nurses and allied health professionals gather to address problems in complex cases which require multi-disciplinary care. This allows the team to have a better understanding of the possible challenges faced by patients during recovery and better tailor the pre/post treatment support.
The Cancer Therapeutics Research Laboratory’s (led by PI Dr Gopal Iyer) theme is identification of prognostic markers, novel therapeutic targets and modification of conventional therapy for head and neck cancers, through individualization of treatment modalities. The lab has established primary cell line and stem cell models for testing of targeted compounds specific to head and neck cancers. The aim is to translate this knowledge into clinical trials and patient specific outcome in the near future.
The Program in Translational and Clinical Liver Cancer Research (led by Professor Pierce Chow) is a multi-institutional and multi-national enterprise with NCCS leading translational research platforms and prospective muti-center clinical studies in HCC. The program currently hosts the NMRC National Flagship Program in Liver Cancer (PLANET 2.0; AHCC12 EMPHASIS), the investigator-initiated multi-national randomized phase II trial involving 13 sites in the Asia-Pacific (AHCC09 STRATUM) and the whole-of-nation prospective cohort study (AHCC10 ELEGANCE), in collaboration with 3 industrial partners, 2 academic institutions, 6 hospitals/specialist clinics and 8 SingHealth polyclinics in Singapore. It also houses the secretariat of the Asia-Pacific Hepatocellular Carcinoma Trials Group which has to date, led more than 10 prospective, multi-centre clinical studies in hepatocellular carcinoma (HCC) involving more than 50 participating centres in 17 countries with more than 4,000 patients enrolled. New clinical studies are in the pipeline and the group has established strong alliance with industry and academia. More information on the AHCC Trials Group can be found on:
Subscribe to our mailing list to get the updates to your email inbox...
30 Hospital Boulevard, 168583 +65 6436 8000